About: Joel Shertok
- Website
- Details
- I'm a Ph.D. chemical engineer with 45 years of experience in the chemical/materials/biotech industries. My specialization is in process/product commercialization and scale-up.
Posts by Joel Shertok:
-
July 5, 2020 The Global Economic Outlook During the COVID-19 Pandemic: A Changed World
-
July 3, 2020 Why We Can’t Foresee the Pandemic’s Long-Term Effects
-
May 16, 2020 The COVID-19 Recovery will be digital: A plan for the First 90 Days
-
April 17, 2020 The Impact Of The Coronavirus Crisis On Mergers And Acquisitions
-
April 13, 2020 When Will Life Be Normal Again? We Just Don’t Know
-
March 21, 2020 Economic Implications of the Coronavirus
-
March 19, 2020 Will the Coronavirus Permanently Change Our Way of Working?
-
December 23, 2019 The Problem and Challenges of Commercialization
Follow Blog via Email
-
Recent Posts
- Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
- Sperm epigenetic clock and pregnancy outcomes May 14, 2022
- Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
- Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
- Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
- Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
- 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
- We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
- The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines April 22, 2022
- The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022
Archives
Categories
Meta
-
2012pharmaceutical
-
Amandeep Kaur
-
Aashir Awan, Phd
-
Abhisar Anand
-
Adina Hazan
-
Alan F. Kaul, PharmD., MS, MBA, FCCP
-
alexcrystal6
-
anamikasarkar
-
apreconasia
-
aviralvatsa
-
David Orchard-Webb, PhD
-
danutdaagmailcom
-
Demet Sag, Ph.D., CRA, GCP
-
Dror Nir
-
dsmolyar
-
Ethan Coomber
-
evelinacohn
-
Gail S Thornton
-
Irina Robu
-
jayzmit48
-
jdpmd
-
jshertok
-
kellyperlman
-
Ed Kislauskis
-
larryhbern
-
Madison Davis
-
marzankhan
-
megbaker58
-
ofermar2020
-
Dr. Pati
-
pkandala
-
Rosalind Codrington, PhD
-
ritusaxena
-
Rick Mandahl
-
sjwilliamspa
-
Srinivas Sriram
-
stuartlpbi
-
Dr. Sudipta Saha
-
tildabarliya
-
vaishnavee24
-
zraviv06
-
zs22
-